Januvia, safe for diabetes but risks heart attack patients
The study at TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin), collected data from more than 14,000 people aged 50 and above who had type 2 diabetes and a history of cardiovascular problems. The researchers focused on 14% of the participants who were aged 75 and were the oldest age group. The group had HbA1c rates of at least 6.5% but not higher than 8%. Among older patients who have well-controlled type 2 diabetes and cardiovascular disease, sitagliptin had neutral effects on cardiovascular risk and raised no significant safety concerns. Related article: What Do You Mean By Statins? A study report stated that Januvia (sitagliptin) is prescribed for the treatment of type 2 diabetes and proved safe for older patients with a history of cardiovascular disease. It is said that this acts to reduce blood glucose levels as it inhibits a dipeptidyl peptidase enzyme. Januvia is intended for the treatment of type 2 diabetes and should only be used after consultation with t